[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"protein-supplementation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:protein-supplementation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,84,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100633575","the-effects-of-peptistrong-and-whey-on-muscle-function-in-older-adults-100633575",false,"NCT07528469","The Effects of PeptiStrong and Whey on Muscle Function In Older Adults","The Effects of PeptiStrong and Low Dose Whey Protein Versus High Dose Whey Protein Alone on Muscle Function In Older Adults","Inclusion Criteria:\n\n* Men and women aged 60 to 85 years at the time of enrolment\n* Community-dwelling (living independently or with minimal assistance)\n* Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)\n* Willing and able to attend two study visits at the research facility (baseline and end of study)\n* Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days\n* Able to understand the study information and provide written informed consent\n\nExclusion Criteria:\n\n* Any known food allergy or intolerance to fava bean protein or milk protein\n* Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated\n* Yes to any of the answers on the \"Older Adult Functional Assessment Screening Questionnaire\"\n* Individuals with implanted electronic devices\n* Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention\n* Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible",true,"ALL","60 Years","85 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Examining the effects of PeptiStrong and protein on muscle function in older adults",[28,29,30,31,32,33,34],"Healthy Ageing","Protein Supplementation","Muscle Health","Muscle Function","Hand Grip Strength","Longevity","Peptides",[36,37,38,39,33,40,41,42,43,44],"Healthy Aging","Protein supplementation","Muscle function","Physical performance","Bioactive peptides","Hand grip strength","Short performance physical battery","Nuritas","Liverpool John Moore University","RECRUITING","2026-04-30",{"date":48,"type":49},"2026-05-06","ACTUAL",{"date":51,"type":49},"2026-04-06",{"date":53,"type":22},"2026-10-30",{"name":55,"class":56},"Nuritas Ltd","INDUSTRY",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":16,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":57},"100592113","protein-supplementation-intervention-on-body-weight-100592113","NCT06989203","Protein Supplementation Intervention on Body Weight","An Intervention Study Investigating Effect of Dietary Protein Supplementation on Body Weight and Metabolic Homeostasis","Inclusion Criteria:\n\n* Aged 20 to 50 years.\n* Normal-weight participants: 18.5 kg\u002Fm² ≤ Body Mass Index (BMI) \\\u003C 24 kg\u002Fm².\n* Overweight or obese participants:\n\nBMI ≥ 28 kg\u002Fm², or 24 kg\u002Fm² ≤ BMI \\\u003C 28 kg\u002Fm² and a clinical diagnosis meeting semaglutide treatment indications (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, cardiovascular disease, etc.).\n\n* Willingness to participate in this study and provide signed informed consent.\n\nExclusion Criteria:\n\n* Abnormal metabolic indicators (meeting any one of the following criteria is grounds for exclusion):\n\n  1\\. Normal weight (18.5 kg\u002Fm² ≤ BMI \\\u003C 24 kg\u002Fm²):\n  1. Waist circumference ≥ 90 cm for men or ≥ 85 cm for women.\n  2. Fasting glucose ≥ 6.1 mmol\u002FL or 2-hour postprandial glucose ≥ 7.8 mmol\u002FL, or a confirmed diagnosis of diabetes.\n  3. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or currently under antihypertensive treatment.\n  4. Fasting triglycerides (TG) ≥ 1.7 mmol\u002FL; high-density lipoprotein cholesterol (HDL-C) \\\u003C 0.9 mmol\u002FL in men or \\\u003C 1.0 mmol\u002FL in women.\n\n  2\\. Overweight or obese (BMI ≥ 24 kg\u002Fm²):\n  1. Fasting plasma glucose \\> 11.1 mmol\u002FL or HbA1c \\> 9%, or previously diagnosed diabetes, or currently using insulin or any antidiabetic medication.\n  2. Blood pressure ≥ 160\u002F100 mmHg, or clinically diagnosed stage 2 or stage 3 (moderate or severe) hypertension, or currently under antihypertensive treatment.\n  3. Use of lipid-lowering drugs (e.g., fibrates, bile acid sequestrants, statins, PCSK9 inhibitors) within the past 3 months, or TG ≥ 5.7 mmol\u002FL, or LDL ≥ 4.9 mmol\u002FL.\n* Pregnancy or lactation.\n* Self-reported weight change of more than 5 kg within the 90 days prior to screening.\n* Use of antibiotics, antimicrobials, or anti-inflammatory\u002Fanalgesic salicylates (e.g., aspirin) within the 3 months prior to screening for 3 days or more.\n* Use of estrogen therapy or other hormonal medications within the past 6 months.\n* Use of GLP-1 receptor agonists or probiotics within the past 3 months.\n* Heavy alcohol consumption (females \\> 40 g\u002Fday, approximately 250 mL of huangjiu \\[yellow rice wine\\], or 1000 mL of beer, or 100 mL of liquor per day; males \\> 80 g\u002Fday).\n* Severe liver or kidney dysfunction (ALT, AST, or serum creatinine exceeding 3 times the upper limit of normal, UACR ≥ 30 mg\u002Fg, or eGFR \\\u003C 60 mL\u002Fmin).\n* Gastrointestinal diseases affecting digestion and absorption (e.g., severe diarrhea, severe constipation, severe inflammatory bowel disease, peptic ulcer, gallstones, cholecystitis).\n* Underwent surgery within the past year (excluding appendectomy or hernia repair).\n* Severe cardiovascular or cerebrovascular diseases (e.g., heart failure, myocardial infarction, stroke, acute myocarditis, severe arrhythmia, or receiving interventional therapy).\n* Presence of metallic implants such as a cardiac stent or pacemaker.\n* Cancer or having received radiation or chemotherapy within the past 5 years.\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia, or a personal history of hyperthyroidism or hypothyroidism.\n* Chronic or acute pancreatitis.\n* Positive hepatitis B surface antigen (HBsAg), active tuberculosis, HIV, or other infectious diseases.\n* Currently participating in another clinical study or having done so within the past 3 months.\n* Claustrophobia.\n* Any psychiatric disorder such as attention-deficit\u002Fhyperactivity disorder (ADHD), bipolar disorder, or epilepsy (including current use of antiepileptic medications), or use of antidepressant medications.\n* Inability to read, write, operate a smartphone, or perform daily activities independently.","20 Years","50 Years",{"count":68,"type":22},140,[25],"This study is a randomized clinical trail with a parallel design, involving 120 overweight\u002Fobese (body-mass index, BMI ≥ 24 kg\u002Fm²) participants and 20 normal-weight participants. Overweight\u002Fobese participants will be randomly allocated to one of three groups: 1) calorie restricted balanced diet (CRD)group; 2) CRD + semaglutide group; or 3) CRD + segaglutide with protein supplementation. Through a 3-month weight loss intervention and 6-month follow-up, this study aims to investigate the effects of dietary protein supplementation combined with semaglutide on weight loss, energy and glucose and lipid metabolism, muscle loss, and weight regain. Additionally, the study will explore key factors affecting intervention efficacy, including obesity phenotypes, gut microbiota profiles, genetic backgrounds, and lifestyle factors, to provide evidence for optimizing individualized intervention strategies.",[72,73,29],"Obesity","Weight Loss","2026-03-16",{"date":76,"type":49},"2026-03-17",{"date":78,"type":49},"2025-06-10",{"date":80,"type":22},"2026-12-31",{"name":82,"class":83},"Chinese Academy of Sciences","OTHER_GOV",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100617748","the-effects-of-medidrink-platinum-and-fava-bean-protein-hydrolysate-on-fitness-in-an-aged-population-100617748","NCT07322653","The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population","Prospective, Open-Label, Multicenter Study to Characterise the Effects of Co-administration of MediDrink Platinum+ Formula Containing Novel Protein Blend SPR-01 and Fava Bean Protein Hydrolysate on Fitness in an Aged Population","Inclusion Criteria:\n\n* 60 years or older\n* BMI ≤ 25 kg\u002Fm²\n* Malnourished (mini nutritional assessment MNA \\\u003C11\n* Sarcopenic: SARC-F score ≥ 4\n* Capable or oral feeding either alone or assisted\n* Ambulatory (WHO PS\u002FECOG 0-3)\n* Ability to complete questionnaires and self assess health status\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Patient cannot eat orally\n* Acute Infection\n* Proven Intestinal obstruction\n* Co-morbidities requiring a special diet (diabetes, kidney disease etc.)\n* Liver dysfunction\n* Acute or chronic renal failure\n* Uncontrollable nausea or vomiting\n* Use of megestrol acetate or metabolic steroids\n* Dietary supplement use in the last 3 months\n* Known intolerance or allergy to the investigational products\n* Participation in any clinical trial within the last 3 months",{"count":92,"type":22},75,[25],"Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia",[96,97,29,98,99,100],"Sarcopenia in Elderly","Malnourished","Muscle Mass","Physical Function","Strength",[102,103,104,105,106,107,108,109,110],"Sarcopenia","Peptide Therapeutics","PeptiStrong","MediDrink Platinum","Malnourished Elderly","Physical functioning","MediDrink Platinum+","Clinical Nurtition","Nutritional status","2025-12-22",{"date":113,"type":49},"2026-01-07",{"date":115,"type":49},"2025-09-10",{"date":117,"type":22},"2027-01-02",{"name":55,"class":56},2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":138,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":57},"100595037","frailty-intervention-in-postoperative-hip-fracture-inpatients-100595037","NCT07027241","Frailty Intervention in Postoperative Hip Fracture Inpatients","Multicomponent Exercise and Nutrition Based Frailty Intervention in Postoperative Hip Fracture Inpatients","Inclusion Criteria:\n\n* Older adults \\>\u002F= 65\n* Clinical Frailty Score 4-6 (This includes patients with very mild, mild and moderate frailty. This would be in keeping with literature quoting frailty interventions where patients who are 'pre-frail' and frail are included)\n* Post fragility hip fracture (including subtrochanteric fracture)\n* Post hip fracture surgery (all types including total hip replacement, hemiarthroplasty, IM nailing)\n* Medically stable postoperatively\n* No weightbearing restriction\n* Mobile pre-admission (including aids and max assist of 1 person)\n\nExclusion Criteria:\n\n* Medically unstable (NEWS \\>3, unless a higher cutoff is stipulated by the primary medical researcher)\n* Non fragility hip fracture (fracture from non osteoporotic aetiology, pathologic fracture)\n* Hip surgery for other aetiology (prosthetic joint infection, arthritis, implant loosening, avascular necrosis, periprosthetic fracture)\n* Polytrauma\n* Delirium or severe cognitive impairment (as defined by inability to follow instructions and unable to provide informed consent)\n* Pre-existing neurologic or cardiovascular disorders that would affect participation\u002F compliance with exercise intervention\n* Open hip fracture\n* Other lower limb orthopaedic disorders that affect participation\u002F compliance with exercise intervention\n* Terminal illness with \\\u003C\u002F= 6 months to live\n* Active treatment for cancer (systemic chemotherapy or radiotherapy, patients on oral chemotherapeutic agents\u002F checkpoint inhibitors will be eligible for inclusion)\n* Nursing Home Resident\n* Severe lower limb pain post-op\n* Severe skin issues\u002F ulcers in non-operated lower limb that would preclude utilisation of ankle weights\n* Swallowing disorders\u002F difficulty\n* Renal impairment with eGFR \\\u003C30\n* Hepatic failure\n* Patients with a dairy\u002F soy allergy","65 Years",{"count":129,"type":22},50,[25],"Hip fracture is a big health concern in older adults, and can lead to increased risk of death, reduced level of independence \\& mobility, reduced quality of life, and higher likelihood of admission to nursing homes. Frailty is a medical condition associated with ageing that results in a reduced ability to do daily tasks. A frail older adult is also less able to recover well from conditions that may affect their wellbeing (for example, infections, falls resulting in injuries or hospital admissions). Frailty is common in older adults with hip fractures.\n\nThere has been increasing research showing that frailty can be slowed down and improved by a combination of nutritional supplementation and exercise. However, most of the research in this area has been in frail older adults living at home or in nursing homes. The exercise or nutritional programs in these studies tend to be carried out over weeks or months. There are very few studies looking at older adults in hospital and how exercise and nutrition help with frailty over shorter periods of time, even more so in patients who have sustained an injury.\n\nThere is, however, very little research in hospital based frailty programs in older patients who have suffered major trauma. It is well known that standing up and starting to walk soon after a hip fracture improves time to recovery, reduces hospital length of stay and death. Hence, physiotherapy on the first day after hip fracture surgery is now recommended. However, there needs to be more research to aid in developing physiotherapy and exercise programs that are safe and doable in the care of hip fracture patients despite limited resources in our healthcare system.\n\nSimilarly, although malnutrition is common in frail older adults with hip fractures, the benefits of nutritional supplementation in these patients is not fully understood. It is known that having a hip fracture puts a person at risk of muscle breakdown and increasing protein intake is recommended to help reduce this risk. Research on exercise and nutrition based frailty programs specific to hip fracture patients is strongly needed, specifically the development of that are doable and safe in the hospital setting that can help improve outcomes in hip fracture patients after surgery.\n\nThe investigators believe that a multicomponent exercise and nutrition based frailty program will be safe, doable and acceptable in frail older adults after hip fracture surgery.",[133,134,135,136,137,29],"Hip Fractures (ICD-10 72.01-72.2)","Frailty at Older Adults","Strength Training","Resistance Training","Exercise Training",[139,140,141,37,142,143],"Hip fracture","Exercise","Nutrition","Strength and resistance training","Frailty","NOT_YET_RECRUITING","2025-06-16",{"date":147,"type":49},"2025-06-18",{"date":149,"type":22},"2025-08-01",{"date":151,"type":22},"2026-02",{"name":153,"class":154},"Royal College of Surgeons, Ireland","OTHER"]